Prof Jarad Martin
@DocJarad
Followers
2K
Following
867
Media
224
Statuses
1K
Radiation Oncologist who treats and researches #prostatecancer, gastrointestinal cancers & benign diseases. Dabbles in #mathematics. Views my own.
Newcastle, Australia
Joined May 2012
Today our 2025 @ANZUPtrials Idea Generation Workshops continue with #ProstateCancer today led by #ProfLisaHorvath & @DocJarad with over 10 concepts being presented #ANZUPconcepts @PCFA @CancerAustralia @Prof_IanD
0
4
12
Thanks for sharing! The @ASTRO_org 2025 AM in San Francisco (Sep 27-Oct 1) will have a 3 hr symposium on Sun featuring RT for non-malignant disease, including cardiac. Your fellow Aussie, @DocJarad, is helping put it together. See you this Fall, if not sooner!
Our little Oz 🦘🇦🇺experience of cardiac ablation for 💔ventricular arrhythmia. 50-day author link here; https://t.co/6cXHNL5A6B. Pictures say a thousand words! Or in this case, re-wiring a few cardiac circuits 😀 @PeterMacRadOnc #radonc
2
3
17
ProPSMA - the gift that keeps on giving! Great to be part of such an impactful collaboration.
Longer follow-up from our landmark ProPSMA study just out @EurUrolOncol: PSMA nodal status is prognostic! At 3 years 70% of patients without nodal involvement (N0) disease free, vs. only 46% if N1 CT-defined nodal status is not prognostic. Read the details here:
1
2
18
Delighted to share the results of #PACE B trial, published in @NEJM today 5 fraction SBRT is non inferior to CRT! https://t.co/9ja6OZFRab
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa
26
161
358
Brachytherapy doses of radiotherapy delivered non-invasively for prostate cancer with 94.1% 5-year control and low rates of significant toxicity. Now being investigated in randomised trials such as @TROGfightcancer NINJA and @GETUG_Unicancer PEACE 7.
Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial by @drericwegener et al https://t.co/7KXd5JKjob
#UroSoMe #MedTwitter #EUO
0
8
16
#STORM trial examines elective nodal radiotherapy in treating #ProstateCancer recurrence. @piet_ost @ugent joins @zklaassen_md @GACancerCenter to discuss, emphasizing that ENRT offers longer disease-free periods and lower pelvic recurrence rates compared to SBRT. #WatchNow >
1
36
68
Tell me again why we can’t use renal SBRT in the UK?!? 100% local control is hard to beat. Masterclass by @_ShankarSiva #ASTRO24
10
62
256
I struggle with when to consider testosterone replacement for symptomatic men with controlled disease after ADT. After either six or 18 months of ADT, spontaneous recovery is rare after the two year mark, so some great data to inform shared decision making.
Pleased to share the newest MARCAP publication, out in @EUplatinum -- the TRANSPORT analysis of T recovery after ADT for localized PCa, led by @weeloonong and Tahmineh Romero Free share link:
2
19
41
Transdermal estradiol as a new option for testosterone lowering vs LHRHa : similar MFS & OS but different toxicity than LHRHa (less hot flashes, higher bone mineral density...) Open Qs: 1. efficacy vs antagonists 2. combination with other drugs (ARPI, PARPi) or RT #ESMO2024
5
28
39
#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients @DrTolan @alison_tree @cpeedell @DrAndrewLoblaw @EmmaHall71 @ProfJOSullivan https://t.co/HlFxb3jegQ
8
114
226
Congratulations @ldawsonmd @RadMedPM @pmcancercentre @UHN @UofTDRO and colleagues across Canada for publishing CCTG HE1 in @TheLancetOncol establishing single fraction RT as an effective palliative treatment for painful liver cancer. @CDNCancerTrials
https://t.co/aFw3lpyv7Z
thelancet.com
Single-fraction radiotherapy plus best supportive care improved pain compared with best supportive care alone in patients with liver cancer, and could be considered a standard palliative treatment.
4
35
112
Word of the Day: PSEUDOGLOT (neologism) - one who knows a few basic words in many languages and pretends to be a polyglot.
20
69
607
Great to see vHDRB going mainstream. Here is our data for 20Gy/2# boost - 94% efficacy, and low toxicity. Experimental arm in ongoing RCTs NINJA and PEACE 7. https://t.co/6Zgh00W6Z5
EBRT Plus Prostate SBRT Boost (19 Gy in 2 Fxs) has been Added to the NCCN Guidelines for Unfavorable Intermediate to Very High Risk Prostate Cancer!
1
2
13
100% agree @DrSpratticus Here's a popular #HIFU company's web posting... Vs data they reference vs other published data... (note their ref has no RP nor RT data). Yes failure def'n different for RP vs RT but drives salvage = more toxicity Maybe they need to hire new webmaster?
@aleberlin2 Can’t emphasize the importance of this being done on trial as patients can’t have informed consent without good data. All treatments have side effects and they need to understand their choices based on quality data and not misguided advertising that is rampant (including medonc
2
7
32
Congratulations @_ShankarSiva. Super excited to have contributed to this important clinical trial, and looking forward to help roll renal #SBRT out as a standard management option for primary #RCC.
1/ For #KidneyCancerAwareness month @TheLancetOncol has a 50-day full link to @TROGfightcancer FASTRACK II! https://t.co/p5SVg9Ktvl. Thank you @CancerAustralia, @ANZUPtrials, @VarianMedSys. A new #radiotherapy standard of care option for inoperable primary #kidneycancer #radonc
0
2
8
How to write an introduction section for a medical research manuscript
4
38
132
Many thanks in particular to all of the patients involved, Eric Wegener for pulling it together, @DavePryorRO for support, and my Co-PI Mark Sidhom.
0
0
2
We are now comparing this promising regimen with 40Gy/5# on our NINJA RCT, expected to complete accrual in 2024. A similar approach is also being investigated as one of the randomisations in PEACE 7. https://t.co/3tGbD5iI7f
bmjopen.bmj.com
Introduction Stereotactic body radiotherapy (SBRT) is a non-invasive alternative to surgery for the treatment of non-metastatic prostate cancer (PC). The objectives of the Novel Integration of New...
1
1
9
Subacute irritative urinary toxicity is not uncommon 6-18 months after treatment, but settles by the 24 month mark for the majority of men. They should generally be reassured rather than over investigated during this time frame.
1
1
7
Like many series using modern radiotherapy, the risk of significant rectal toxicity is very low.
1
0
9